1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

No Safety Shortcuts Under Breakthrough Designation, Synthetic Biologics Finds

 
• By Bridget Silverman

Synthetic Biologics emerged from meetings with US FDA without its breakthrough designation, but with hope that agency will allow decoupling of safety and efficacy endpoints in planned Phase III trial for prevention of C. difficile infection.

Breaking through wall
Please wear your safety googles when attempting a breakthrough.

The narrative surrounding the US FDA’s Breakthrough Therapy Designation (BTD) program has largely focused on its successes in expediting drugs with promising preliminary efficacy for serious unmet medical needs, but the loss of Synthetic Biologics Inc.’s designation for ribaxamase highlights the agency’s strict scrutiny of safety data as well.

Synthetic Biologics voluntarily withdrew the BTD after FDA further reviewed data and analyses from the Phase IIb trial that supported...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.